絞り込み

18453

広告

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.

著者 Gogas HJ , Flaherty KT , Dummer R , Ascierto PA , Arance A , Mandala M , Liszkay G , Garbe C , Schadendorf D , Krajsova I , Gutzmer R , Sileni VC , Dutriaux C , de Groot JWB , Yamazaki N , Loquai C , Gollerkeri A , Pickard MD , Robert C
Eur J Cancer.2019 Aug 19 ; 119():97-106.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (19view , 0users)
Dual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-mutant metastatic melanoma and has historically been associated with grade III pyrexia or photosensitivity depending on the combination used. The objective of this study was to fully describe adverse events from the COLUMBUS study evaluating the most recent BRAF/MEK inhibitor combination encorafenib+binimetinib.
PMID: 31437754 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード